Baxter Hlthcare Corp Drug Patent Portfolio
Baxter Hlthcare Corp owns 7 orange book drugs protected by 29 US patents with Clinolipid 20% having the least patent protection, holding only 1 patent. And Nouress with maximum patent protection, holding 19 patents. Given below is the list of Baxter Hlthcare Corp's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12447190 | 27 Sep, 2044 | Active | |
| US11173189 | Daptomycin formulations containing a combination of sorbitol and mannitol | 11 Mar, 2041 | Active |
| US12097170 | Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation | 08 Mar, 2041 | Active |
| US12290494 | Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation | 08 Mar, 2041 | Active |
| US10493051 | Cysteine composition and injection | 15 Mar, 2039 | Active |
| US10543186 | Cysteine composition and injection | 15 Mar, 2039 | Active |
| US10702490 | Cysteine composition and injection | 15 Mar, 2039 | Active |
| US11045438 | Cysteine composition and injection | 15 Mar, 2039 | Active |
| US11510941 | Stable, highly pure L-cysteine compositions for injection and methods of use | 02 Mar, 2039 | Active |
| US10478453 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10583155 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10653719 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10905713 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10905714 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10912795 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10918662 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10933089 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11510942 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11642370 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11648262 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11679125 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11684636 | Stable, highly pure l-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11826383 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US12403173 | 15 Dec, 2037 | Active | |
| US6900184 | Compositions containing pipercillin and tazobactam useful for injection | 14 Apr, 2023 | Expired |
| US7915229 | Compositions containing piperacillin and tazobactam useful for injection | 14 Apr, 2023 | Expired |
| US8133883 | Compositions containing piperacillin and tazobactam useful for injection | 14 Apr, 2023 | Expired |
| US6207661 | Premixed formulation of piperacillin sodium and tazobactam sodium injection | 22 Feb, 2019 | Expired |
| US5840757 | Lipid emulsion intended for parenteral or enteral feeding | 24 Nov, 2015 | Expired |
Latest Legal Activities on Baxter Hlthcare Corp's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Baxter Hlthcare Corp.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 15 Apr, 2024 | US8133883 |
|
Email Notification
Critical
| 29 Dec, 2023 | US10702490 |
| Mail O.P. Petition Decision | 29 Dec, 2023 | US10702490 |
| Mail-Record Petition Decision of Granted to Make Entity Status large | 26 Dec, 2023 | US10702490 |
| Record Petition Decision of Granted to Make Entity Status large | 22 Dec, 2023 | US10702490 |
| O.P. Petition Decision | 22 Dec, 2023 | US10702490 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Nov, 2023 | US10653719 |
|
Maintenance Fee Reminder Mailed
Critical
| 30 Oct, 2023 | US8133883 |
| Payment of Maintenance Fee under 1.28(c) | 16 Oct, 2023 | US10702490 |
| Petition Entered | 16 Oct, 2023 | US10702490 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 15 Oct, 2023 | US10702490 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 11 Oct, 2023 | US10702490 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 11 Oct, 2023 | US10702490 |
| Post Issue Communication - Certificate of Correction | 27 Sep, 2023 | US11510942 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Aug, 2023 | US10583155 |
Baxter Hlthcare Corp's Drug Patent Litigations
Baxter Hlthcare Corp's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 01, 1, against patent number US5840757. The petitioner , challenged the validity of this patent, with DUTOT as the respondent. Click below to track the latest information on how companies are challenging Baxter Hlthcare Corp's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11642370 | February, 2024 |
Institution Denied
(08 Aug, 2024)
| Exela Pharma Sciences, LLC | Nexus Pharmaceuticals LLC |
| US10653719 | September, 2020 |
Institution Denied
(23 Apr, 2021)
| Exela Pharma Sciences LLC | Eton Pharmaceuticals, Inc. |
| US10583155 | June, 2020 |
Institution Denied
(15 Dec, 2020)
| Exela Pharma Sciences, LLC | Eton Pharmaceuticals Inc. |
| US10583155 | June, 2020 |
Terminated-Denied
(15 Dec, 2020)
| Exela Pharma Sciences, LLC | Eton Pharmaceuticals Inc. |
| US10478453 | May, 2020 |
Institution Denied
(18 Nov, 2020)
| Exela Pharma Sciences, LLC | Eton Pharmaceuticals, Inc. |
| US5840757 | January, 1 |
Decision
(29 Jul, 1998)
| DUTOT | |
Baxter Hlthcare Corp's Family Patents
Recently granted tentative Approvals to Baxter Hlthcare Corp
These tentative approvals reflect continued regulatory progress across both innovative and generic submissions related to Baxter Hlthcare Corp's portfolio.
Innovator tentative approvals
| Drug Name | Active Ingredient | Submission Type | Submission Category | Submission Date |
|---|---|---|---|---|
| Epinephrine Bitartrate In 0.9% Sodium Chloride | Epinephrine Bitartrate |
SUPPL-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Manufacturing (CMC) | 29 Sep, 2025 |
| Argatroban | Argatroban |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 5 - New Formulation or New Manufacturer | 28 Jul, 2010 |
Generic tentative approvals
| Drug Name | Active Ingredient | Submission Type | Submission Category | Submission Date |
|---|---|---|---|---|
| Propofol | Propofol |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | (Not Available) | 23 Dec, 1998 |
Explore deeper patents analysis
Baxter Hlthcare Corp Drug List
Given below is the complete list of Baxter Hlthcare Corp's drugs and the patents protecting them.
1. Clinolipid 20%
Clinolipid 20% is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5840757 | Lipid emulsion intended for parenteral or enteral feeding |
24 Nov, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clinolipid 20%'s drug page
2. Dapzura Rt
Dapzura Rt is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11173189 | Daptomycin formulations containing a combination of sorbitol and mannitol |
11 Mar, 2041
(15 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dapzura Rt's drug page
3. Micafungin In Sodium Chloride 0.9%
Micafungin In Sodium Chloride 0.9% is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12403173 |
15 Dec, 2037
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Micafungin In Sodium Chloride 0.9%'s drug page
4. Norepinephrine Bitartrate In 5% Dextrose
Norepinephrine Bitartrate In 5% Dextrose is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12097170 | Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation |
08 Mar, 2041
(15 years from now)
| Active |
| US12290494 | Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation |
08 Mar, 2041
(15 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Norepinephrine Bitartrate In 5% Dextrose's drug page
5. Nouress
Nouress is protected by 19 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10493051 | Cysteine composition and injection |
15 Mar, 2039
(13 years from now)
| Active |
| US10543186 | Cysteine composition and injection |
15 Mar, 2039
(13 years from now)
| Active |
| US10702490 | Cysteine composition and injection |
15 Mar, 2039
(13 years from now)
| Active |
| US11045438 | Cysteine composition and injection |
15 Mar, 2039
(13 years from now)
| Active |
| US11510941 | Stable, highly pure L-cysteine compositions for injection and methods of use |
02 Mar, 2039
(13 years from now)
| Active |
| US10478453 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10583155 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10653719 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10905713 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10905714 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10912795 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10918662 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10933089 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11510942 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11642370 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11648262 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11679125 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11684636 | Stable, highly pure l-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11826383 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nouress's drug page
Explore Our Curated Drug Screens
6. Vasopressin In Sodium Chloride 0.9%
Vasopressin In Sodium Chloride 0.9% is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12447190 |
27 Sep, 2044
(18 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vasopressin In Sodium Chloride 0.9%'s drug page
7. Zosyn In Plastic Container
Zosyn In Plastic Container is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6900184 | Compositions containing pipercillin and tazobactam useful for injection |
14 Apr, 2023
(2 years ago)
| Expired |
| US7915229 | Compositions containing piperacillin and tazobactam useful for injection |
14 Apr, 2023
(2 years ago)
| Expired |
| US8133883 | Compositions containing piperacillin and tazobactam useful for injection |
14 Apr, 2023
(2 years ago)
| Expired |
| US6207661 | Premixed formulation of piperacillin sodium and tazobactam sodium injection |
22 Feb, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zosyn In Plastic Container's drug page